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SUMMARY: The biopharmaceutical industry has been slow in carrying out LCA 
analyses. However, as the industry matures, the level of scrutiny placed on this industry 
by international governments will increase and hence, there is an urgent need for the 
industry to implement decision-support tools for the decision-making processes. 
Decision-support tools based on life cycle assessment (LCA) can be potentially used for 
application in the biopharmaceutical industry as an aid to decision making. This paper 
sets out the challenges associated with developing such decision-support LCA tools. 
This paper highlights that in order for the industry to overcome these challenges and 
successfully develop decision-support LCA tools, they require a broader understanding 
of the biopharmaceutical manufacturing processes and LCA methodology. 
1. INTRODUCTION 
It is claimed that achieving sustainable development would bring immense benefits to 
organisations, governments and society through better environmental, economical and 
social development (Murphy and Drexage, 2010). However, sustainable development 
will not be achieved if climate change issues remain. The power to achieve sustainable 
development lies solely with governments who need to encourage business 
investments in low carbon technologies and green innovations. Internationally, 
governments are focusing on developing policies for organisations to address climate 
change issues. The strategies and policies are being developed especially for the 
energy-intensive industries (EIIs) because they are one of the major contributors to 
GHG emissions. The iron and steel, the chemical, the petroleum, the pulp and paper, 
the pharmaceutical and the biotechnology industries are all EIIs, and they are 
responsible for 45% of all business and public sector GHG emissions (Bullock, 2011; 
POST, 2012).  
The biopharmaceutical industry focuses on healthcare, and it is an important part of 
the wider biotechnology industry (Mehta, 2008). This industry is a relatively new EII, and 
it is energy-intensive (Accenture, 2012). The biopharmaceutical industry employs 
biological processes to create useful commercial drugs such as monoclonal antibodies, 
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hormones, fusion proteins and vaccines through genetic manipulation of living 
organisms (Farid et al., 2008; Aggarwal, 2010). The biopharmaceutical industry is a fast 
growing industry with increased levels of production demand and a strong pipeline of 
drugs (Mehta, 2008). As the number of biologic drugs emerging from clinical 
development rises, manufacturers are now being prompted to find flexible, cost-efficient 
and environmentally feasible solutions for global scales of production. 
The biopharmaceutical industry uses a range of manufacturing operations to achieve 
the exacting standards needed for drugs, run in either a traditional mode where 
equipment is cleaned in between batches or in single-use mode where no such 
cleaning is required (Farid et al., 2008; Sinclair et al., 2008). Traditional batch 
processing still remains the predominant approach to manufacturing with items largely 
constructed of stainless steel. Although the traditional manufacturing processes 
employing stainless steel equipment are well-established, several issues can be 
identified including high levels of water consumption (mainly for CIP and SIP 
operations), long process times and high capital investments (attributed to stainless 
steel equipment manufacture and assembly) (Mirasol, 2008). These issues are driving 
the industry to seek alternative manufacturing routes.  
One such alternative relies upon the deployment of single-use technologies, which 
employ disposable equipment. Such single-use manufacturing process technologies 
can offer many benefits which include reduction in water consumption, reduction in the 
facility footprint, reduction in the high capital investment associated with stainless steel 
equipment, reduction in the frequency of process cross-contamination and process time 
reductions (Mirasol, 2008; Shukla and Gottschalk, 2012). Although single-use 
technologies can provide many benefits, there are several limitations associated with 
this type of manufacturing process. These include limited production scale (highest 
currently available volume of bioreactor is 2000 L), production of leachables and 
extractables by the single-use bags that could contaminate the product, potential 
adverse effects to the environment due to the increased solid waste levels inherent in 
operation with single-use components (Mirasol, 2008; Sinclair et al., 2008; European 
Commission, 2009; Eibl et al., 2010). Moreover, it is not clear how the environmental 
impacts of single-use items contribute to mitigating the consequences of normal 
operation using extensive water-based cleaning. 
Whilst there are many established decision-support tools and methodologies to 
determine the process economics and efficiencies of alternative technologies and 
strategies, only limited information is known as to the environmental contributions of 
these manufacturing alternatives (Farid, 2007).  It has been argued that the economics 
and efficiency aspects of the processes alone should not drive the biopharmaceutical 
industry’s decision making process; the environmental aspects of processes must also 
influence the decision making process for an industry committed to improving the 
quality of human lives (Mauter, 2009).  
The environmental decision-support tools for the biopharmaceutical industry can be 
developed using LCA methodology. The methodology is based upon a comprehensive 
analysis which estimates the cumulative environmental impacts of the process, product 
or activity, avoiding shifting of the environmental issues from one stage to another or 
from one media to another (Curran, 2006). The methodological framework developed 
by the International Organisation for Standardisation (ISO) to conduct LCA studies is 
widely adopted and consists of four phases: goal definition and scope, life cycle 
inventory analysis (LCI), life cycle impacts assessment (LCIA) and interpretation 
(Curran, 2006). Although other environmental tools such as Risk Assessment (RA), 
Material Flow Analysis (MEA), Technology Assessment (TA), and Environmental 
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Management System (EMS) exist, LCA is the only environmental tool that is process-
orientated (Baumann and Tillman, 2009). It is also the only tool that can provide a 
comprehensive evaluation of the environmental burdens of a given manufacturing 
process without shifting the burdens from one phase/stage to another (Curran, 2006). 
These characteristics make LCA tools ideal for decision-support to aid decision-making 
processes when matched with similar tools for process selection and efficient waste 
management (Beaver, 2000).  
This paper sets out the challenges associated with developing decision-support LCA 
tools for the biopharmaceutical industry. In the subsequent section of the paper, the 
challenges are elaborated and, where possible, recommendations are provided to 
address them effectively. These challenges may be relevant to many LCA efforts, 
however the focus of this paper is on the biopharmaceutical industry. 
 
 
2.  FOUR CHALLENGES OF DEVELOPING DECISION-SUPPORT TOOLS BASED 
ON LCA FOR THE BIOPHARMACEUTICAL INDUSTRY 
 
It has been established that decision-support tools based on LCA are imperative for 
the biopharmaceutical industry as an aid to decision-making.  Such decision-support 
LCA tools will allow the industry to select environmentally favourable manufacturing 
processes. However, there are four challenges that must be addressed before decision-
support LCA tools can be successfully implemented in the industry. The challenges 
include; i) selecting the LCA system boundary for the manufacturing processes, ii) 
selecting the appropriate type of LCA approach for the decision-support tools, iii) 
obtaining the LCI inventory data, and iv) verifying the LCI inventory data.  We shall now 
consider each in turn. 
 
 
2.1 Selecting the LCA system boundary approach for the manufacturing 
processes 
 
There are different LCA system boundary approaches that can be considered for a 
decision-support tool and they include; i) Cradle-to-grave, ii) Cradle-to-gate, and iii) 
Gate-to-gate. The cradle-to-grave LCA system boundary approach involves the 
evaluation of environmental impacts of a product/process from its raw material 
extraction and refining through component manufacturing, distribution, use and disposal 
at end-of-life (includes the supply-chain, use and end-of-life phases) (Pietrzykowski et 
al., 2011). In the cradle-to-gate LCA system boundary approach the evaluation of 
environmental impacts of a product/process from its raw material extraction and refining 
through component manufacturing, distribution and use (includes the supply-chain and 
use phases) is made. The cradle-to-gate LCA system boundary approach does not 
account for the end-of-life phase of a product/process (Kara et al., 2010). Finally the 
gate-to-gate LCA system boundary approach involves the evaluation of environmental 
impacts of a product/process during its use phase. The gate-to-gate LCA system 
boundary approach does not account for the supply-chain and end-of-life phases of a 
product/process (Puettmann and Wilson, 2005). Three schematic representations of the 
LCA system boundary approaches are provided (see Figs 1, 2 and 3 below). These 
schematic diagrams, based on a typical biopharmaceutical manufacturing process 
(monoclonal antibody manufacturing process), illustrate the differences between each 
system boundary approach. 
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Figure 1. The LCA analysis of a monoclonal antibody manufacturing process using 
cradle-to-grave system boundary approach. 
 
Figure 2. The LCA analysis of a monoclonal antibody manufacturing process using 
cradle-to-gate system boundary approach. 
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Figure 3. The LCA analysis of a monoclonal antibody manufacturing process using 
gate-to-gate system boundary approach. 
Selecting the appropriate type of LCA system boundary for decision-support tools 
can be challenging as the current LCA methodologies and the standards set by the ISO 
create difficulties for defining system boundaries (Suh et al., 2003).  It should be 
acknowledged that failure to define properly the system boundaries could cause the 
tools to be invalid (Matthews and Small, 2001). This is because important activities that 
may have huge impacts are not modeled by the decision-support tools. An LCA 
practitioner should analyse the objectives of a given study carefully and draw an initial 
system boundary. Further refinements should be made to the initial system boundary by 
including processes that are shown to be significant by sensitivity analysis (Suh et al., 
2003).  
 
 
2.2 Selecting the appropriate type of LCA approach for the decision-support tools 
 
Consequential LCA (CLCA), Attributional LCA (ALCA) and Attributional LCA with 
system expansion are three different LCA approaches that aim to answer different 
questions, therefore the two LCA approaches must be distinguished (Finnveden, 2008). 
CLCA is an approach commonly used by decision makers where the main aim is to 
identify the cause and effect relationship between possible decisions and the 
environmental burdens (Mathiesen et al., 2009). ALCA is ideal for consumption-based 
accounting as it focuses on describing the environmentally relevant physical flows to 
and from a life cycle and its sub-systems (Finnveden, 2008). ACLA with system 
expansion is a hybrid between ALCA and CLCA. The similarities and differences of the 
three LCA approaches are highlighted in Table 1. The choice of LCA approach should 
be based on the objectives and applications of a decision-support tool. This is because 
the appropriate LCA approach depends on the objectives of a decision-support tool 
(Finnveden et al., 2009). 
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Table 1. Characteristics of LCA approaches (Baumann and Tillman, 2009) 
 ALCA CLCA ALCA with 
System Expansion 
Choice of Data Average Marginal Average 
Allocation 
Procedure 
Partitioning System 
Expansion 
System 
Expansion 
Application Consumption-
Based Accounting 
Change-Oriented 
LCA 
Consumption-
Based Accounting 
System 
Subdivision 
- Foreground & 
Background 
Foreground & 
Background 
 
 
2.3 Obtaining the LCI data for biopharmaceutical processes & verifying the data 
 
Obtaining the LCI data for a biopharmaceutical manufacturing process can be a 
challenge given the relative lack of experience with LCA in the industry. Unlike other 
industries, only limited numbers of biotech LCA studies exists and hence LCI data for 
biopharmaceutical processes are not readily available (Newman, 2010; Pietrzykowski et 
al., 2011; Mauter, 2009; Pietrzykowski et al., 2013). There are no databases specific to 
the biopharmaceutical industry, thus, data seeking for studies on biopharmaceutical 
processes can be laborious. This challenge could be addressed by using data from 
similar industries such as the chemical and pharmaceutical industries, by carrying out 
interviews with experts from the industry, and also by carrying out suitable literature 
surveys and analyses. A proper data collection procedure is needed and will help the 
industry to collect more easily the relevant LCI data needed for the decision-support 
tools development (Udo De Haes et al., 2002). 
Upon obtaining the data, there is a need to verify the LCI data to determine their 
validity. This represents another challenge for the decision-support tools development. 
The biopharmaceutical industry lack the methods needed to validate the data. However, 
the industry could respond to this challenge by again comparing the data with that from 
similar industries (e.g. chemical and pharmaceutical). This is possible because the 
manufacturing processes share common features (Mata et al., 2012). The industry 
could also validate the robustness of the LCI data by carrying out sensitivity and 
uncertainty analyses (Baumann and Tillman, 2009; Pietrzykowski et al., 2013). 
Sensitivity analyses evaluate how parameter choices affect the outcome of an LCA 
study (Pietrzykowski et al., 2013). They are used to identify the key parameters in a 
study that tend to affect the outcome of the study more than others (Pietrzykowski et al., 
2013). Uncertainty analyses evaluate the effect of imprecise data on the outcome of an 
LCA study (Baumann and Tillman, 2009; Pietrzykowski et al., 2013).  Data are 
considered to be imprecise because they can range over an internal (Baumann and 
Tillman, 2009). To carry out uncertainty analyses, all the varying data must be collected 
in order to establish interval and distribution (Baumann and Tillman, 2009). Once 
conducted the results of such analyses give further confidence in the prediction made 
Sardinia 2013, Fourteenth International Waste Management and Landfill Symposium  
 
and hence of the value of the model to real-life decision-making. 
 
 
 
 
 
3. CONCLUSIONS 
 
Increasing pressure exerted by international governments on the EIIs is driving these 
industries to reduce their environmental impacts. Industries such as the energy, 
automotive, chemical and pharmaceutical have been employing LCA to predict the 
environmental impacts of their processes, thus enabling these industries to implement 
engineering measures designed to reduce their impact, and in particular by employing 
low carbon technologies (Saur et al., 2006). The biopharmaceutical industry has been 
slow in carrying out LCA analyses. However, as the industry matures, the level of 
scrutiny placed on this industry by international governments will increase and hence, 
there is an urgent need for the industry to implement decision-support tools in their 
decision-making process. 
LCA is an ideal methodology to be used by the industry as a basis for their decision-
support tools. As an environmental management tool, these take into account all of the 
potential environmental impacts of a process, from resource extraction to final disposal 
(without shifting the impacts from one stage to another) (Mietinen and Hamalainen, 
1997). Thus, this makes them ideal tools to be used as an aid to decision making in the 
biopharmaceutical industry. 
The aim of the paper was to set out the challenges of developing decision-support 
LCA tools for the biopharmaceutical industry. The paper identifies that broader 
understanding of both the biopharmaceutical processes and of the relevant life cycle 
assessment methodologies are required for the successful development of decision-
support LCA tools. The challenges identified should not be seen as hurdles to be 
cleared, but rather as learning opportunities for the industry. By addressing the 
challenges, the industry can move to a position where the manufacture of drugs is 
achieved in the most sustainable fashion. This will allow the industry to be a step closer 
towards achieving sustainability. 
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